The pooled results indicated that there is a statistically significant relationship between the ERCC1 rs11615 polymorphism and increased breast cancer risk in all genetic models: the allele model (OR = 1.21, 95% CI = 1.06–1.39, P=0.006), homozygous model (OR = 1.29, 95% CI = 1.06–1.59, P=0.013), heterozygote model (OR = 1.26, 95% CI = 1.10–1.44, P=0.001), recessive model (OR = 1.20, 95% CI = 1.01–1.43, P=0.036), and dominant model (OR = 1.27, 95% CI = 1.12–1.44, P<0.001) (Table 2 and Figure 2). Here, ERCC1 is linked to breast carcinoma.